These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34496561)

  • 1. Allosteric Inhibition of Parkinson's-Linked LRRK2 by Constrained Peptides.
    Helton LG; Soliman A; von Zweydorf F; Kentros M; Manschwetus JT; Hall S; Gilsbach B; Ho FY; Athanasopoulos PS; Singh RK; LeClair TJ; Versées W; Raimondi F; Herberg FW; Gloeckner CJ; Rideout H; Kortholt A; Kennedy EJ
    ACS Chem Biol; 2021 Nov; 16(11):2326-2338. PubMed ID: 34496561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization.
    Pathak P; Alexander KK; Helton LG; Kentros M; LeClair TJ; Zhang X; Ho FY; Moore TT; Hall S; Guaitoli G; Gloeckner CJ; Kortholt A; Rideout H; Kennedy EJ
    ACS Chem Neurosci; 2023 Jun; 14(11):1971-1980. PubMed ID: 37200505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric inhibition of LRRK2, where are we now.
    Soliman A; Cankara FN; Kortholt A
    Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.
    Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Rab-RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's disease.
    Alexander KK; Naaldijk Y; Fasiczka R; Brahmia B; Chen T; Hilfiker S; Kennedy EJ
    J Pept Sci; 2024 May; 30(5):e3563. PubMed ID: 38135900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
    Chen J; Chen Y; Pu J
    Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin B
    Schaffner A; Li X; Gomez-Llorente Y; Leandrou E; Memou A; Clemente N; Yao C; Afsari F; Zhi L; Pan N; Morohashi K; Hua X; Zhou MM; Wang C; Zhang H; Chen SG; Elliott CJ; Rideout H; Ubarretxena-Belandia I; Yue Z
    Cell Res; 2019 Apr; 29(4):313-329. PubMed ID: 30858560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.
    Sen S; Webber PJ; West AB
    J Biol Chem; 2009 Dec; 284(52):36346-36356. PubMed ID: 19826009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
    Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
    PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
    Scott JD; DeMong DE; Greshock TJ; Basu K; Dai X; Harris J; Hruza A; Li SW; Lin SI; Liu H; Macala MK; Hu Z; Mei H; Zhang H; Walsh P; Poirier M; Shi ZC; Xiao L; Agnihotri G; Baptista MA; Columbus J; Fell MJ; Hyde LA; Kuvelkar R; Lin Y; Mirescu C; Morrow JA; Yin Z; Zhang X; Zhou X; Chang RK; Embrey MW; Sanders JM; Tiscia HE; Drolet RE; Kern JT; Sur SM; Renger JJ; Bilodeau MT; Kennedy ME; Parker EM; Stamford AW; Nargund R; McCauley JA; Miller MW
    J Med Chem; 2017 Apr; 60(7):2983-2992. PubMed ID: 28245354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 regulates production of reactive oxygen species in cell and animal models of Parkinson's disease.
    Keeney MT; Rocha EM; Hoffman EK; Farmer K; Di Maio R; Weir J; Wagner WG; Hu X; Clark CL; Castro SL; Scheirer A; Fazzari M; De Miranda BR; Pintchovski SA; Shrader WD; Pagano PJ; Hastings TG; Greenamyre JT
    Sci Transl Med; 2024 Oct; 16(767):eadl3438. PubMed ID: 39356746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants.
    Ilieva NM; Hoffman EK; Ghalib MA; Greenamyre JT; De Miranda BR
    Neurobiol Dis; 2024 Jun; 196():106522. PubMed ID: 38705492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for chemical modulators for LRRK2.
    Mortiboys H
    Biochem Soc Trans; 2016 Dec; 44(6):1617-1623. PubMed ID: 27913670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.
    Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
    Neurochem Res; 2016 Oct; 41(10):2675-2692. PubMed ID: 27394417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
    Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE
    Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-rich repeat kinase 2 and Parkinson's disease.
    Kang UB; Marto JA
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.